Field of the invention

The present invention relates to anti-glycation compositions. More particularly, it relates to compositions comprising a combination of carboxylic acid and an extract of a plant material exhibiting synergistic anti–glycation properties.
Background and prior art
Advanced glycation end products (AGEs), are a diverse group of highly oxidant compounds with a pathogenic significance in aging, diabetes and several other chronic diseases. AGEs are generated through a non-enzymatic reaction between reducing sugars and free amino groups of proteins, lipids, or nucleic acids. Some of the AGEs have fluorescent properties. Advanced glycation occurs over a period of weeks, thereby affecting long-lived proteins and the structural components of the connective tissue matrix, such as collagen, which is one of its prime targets. The formation of AGEs is influenced by several factors, like sugar concentration, chemical structure, turnover rate of target protein and the degree of oxidative stress in the environment. Glucose has the slowest glycation rate, whereas the intracellular sugars, such as glucose-6-phosphate and fructose forms AGE at faster rates.
According to the ‘glycation hypothesis of aging’ accumulation of AGE products alters the structural properties of tissue proteins and reduces their susceptibility to catabolism. Consequently contributing to the aging of tissues. Evidences suggest that there is an age dependent increase in glycation products.
CN 102355884 B discloses advanced glycation end product degradation agent as a cosmetic composition or food composition. It discloses use of an unsaturated fatty acid as anti-glycation active ingredient the anti-glycation composition may comprise ingredients including plant extracts.
US 6531608 B2 discloses synthesis of certain complexes of L-cysteine, N-acetyl Lcysteine, N-(2-mercapto-propionyl) glycine, L-2-oxothiazolidine-4-carboxylate and the nutritional or clinical use thereof. US‘608 teaches the effect of synthesized compounds on diabetes which is a result of non-enzymatic protein glycation.
US 20090074822 A1 discloses cosmetic composition for ameliorating the adverse effects of aging and sun damage. The composition comprises of Alpha glucosidase inhibitors in the range of 0.0001 to 75% including some plant extracts, such as extracts from Salacia reticulata, Scutellaria Baicalensis.
US 20070048243 A1 discloses cosmetic or dermatological topical composition comprising an extract from Criste Marine (i.e. Crithmum maritimum). It particularly discloses that the combination of Crithmum maritimum and Padina pavonica has cosmetic benefits.
WO 2009074409 A1 discloses cosmetic compositions intended for the photoprotection of keratinous materials. The composition includes anti-glycation agents; agents stimulating the proliferation of keratinocytes include Hydrangea macrophylla leaf extract and desquamating agent or depigmentation agent to include 2-oxothiazolidine-4-carboxylic acid (procysteine) and its derivatives.
At the same time, there is always need for more efficient, easily available actives for anti-glycation compositions that synergistically inhibit the formation of advanced glycation end products. The demand for cosmetic compositions and cosmetic methods for skin-glycation products has grown enormously.

Accordingly the present invention provides anti-glycation compositions comprising (R)-(-)-2-oxothiazolidine-4-carboxylic acid and an extract of a plant material selected from a group of plant extracts at specific concentrations exhibiting synergistic inhibition of glycation.

Objects of the invention
It is an object of the present invention to provide a composition for synergistically inhibiting glycation.
It is another object of the present invention to provide synergistic anti-glycation compositions comprising (R)-(-)-2-oxothiazolidine-4-carboxylic acid and an extract of a plant material of Crithmum maritimum at specific concentrations.

It is yet another object of the present invention to provide synergistic anti-glycation compositions comprising (R)-(-)-2-oxothiazolidine-4-carboxylic acid and an extract of a plant material of Hydrangea macrophylla at specific concentrations.

It is another object of the present invention to provide synergistic anti-glycation compositions comprising (R)-(-)-2-oxothiazolidine-4-carboxylic acid and an extract of a plant material of Scutellaria baicalensis at specific concentrations.

It is another object of the present invention to provide synergistic anti-glycation compositions comprising (R)-(-)-2-oxothiazolidine-4-carboxylic acid and an extract of a plant material of Houttuynia cordata at specific concentrations.

It is another object of the present invention to provide synergistic anti-glycation compositions comprising (R)-(-)-2-oxothiazolidine-4-carboxylic acid and an extract of a plant material of Salacia reticulata at specific concentrations.

It is another object of the present invention to provide a method for inhibiting glycation effectively by using either the composition or the formulation.
It is further object of the present invention to provide a process for preparing the formulation comprising the composition.
Summary of the invention
An aspect of present invention is to provide an anti-glycation composition comprising: a) (R)-(-)-2-oxothiazolidine-4-carboxylic acid; and b) plant extract of Crithmum maritimum.
Another aspect of present invention is to provide an anti-glycation composition comprising: a) (R)-(-)-2-oxothiazolidine-4-carboxylic acid; and b) plant extract of Hydrangea macrophylla.
Yet another aspect of present invention is to provide an anti-glycation composition comprising: a) (R)-(-)-2-oxothiazolidine-4-carboxylic acid; and b) plant extract of Scutellaria baicalensis.
A further aspect of present invention is to provide an anti-glycation composition comprising: a) (R)-(-)-2-oxothiazolidine-4-carboxylic acid; and b) plant extract of Houttuynia cordata.
Also an aspect of present invention is to provide an anti-glycation composition comprising: a) (R)-(-)-2-oxothiazolidine-4-carboxylic acid; and b) plant extract of Salacia reticulata.

Another further aspect of present invention is to provide a method for inhibiting glycation effectively by using either the composition or the formulation.
Yet another aspect of present invention is to provide a process for preparing the formulation comprising the compositions.

Description of the invention
The following description is provided to assist in a comprehensive understanding of exemplary embodiments of the invention. It includes various specific details to assist in that understanding but these are to be regarded as merely exemplary.

Accordingly, those of ordinary skill in the art will recognize that various changes and modifications of the embodiments described herein can be made without departing from the scope of the invention. In addition, descriptions of well-known functions and constructions are omitted for clarity and conciseness.

The term “glycation” in context of the present disclosure includes but is not limited to skin-glycation, cataract and stiffening of veins.

The present invention provides personal care compositions. The anti-glycation composition comprises a mixture of (R)-(-)-2-oxothiazolidine-4-carboxylic acid and an extract being second extract selected from a group consisting of extracts of plant material of Crithmum maritimum, Hydrangea macrophylla, Scutellaria baicalensis, Houttuynia cordata and Salacia reticulata.

The inventors have surprisingly found that the combination of (R)-(-)-2-oxothiazolidine-4-carboxylic acid and extract of plant material selected from the group consisting of Crithmum maritimum, Hydrangea macrophylla, Scutellaria baicalensis, Houttuynia cordata and Salacia reticulata at specific concentrations exhibit synergistic anti-glycation properties.

In one embodiment the anti-glycation composition comprises (R)-(-)-2-oxothiazolidine-4-carboxylic acid and an extract of Crithmum maritimum. It was found that the composition exhibits synergism when the concentration of (R)-(-)-2-oxothiazolidine-4-carboxylic acid in a buffer is 1000 ppm, the concentration of the extract in a buffer is 1000 ppm.

In one embodiment the anti-glycation composition comprises (R)-(-)-2-oxothiazolidine-4-carboxylic acid and an extract of Hydrangea macrophylla. It was found that the composition exhibits synergism when the concentration of (R)-(-)-2-oxothiazolidine-4-carboxylic acid in a buffer is 10 ppm, the concentration of the extract in a buffer is 1000 ppm.
In another embodiment the anti-glycation composition comprises (R)-(-)-2-oxothiazolidine-4-carboxylic acid and an extract of Scutellaria baicalensis. It was found that the composition exhibits synergism when the concentration of (R)-(-)-2-oxothiazolidine-4-carboxylic acid in a buffer is 10 ppm, the concentration of the extract in a buffer is 1000 ppm.
In another embodiment the anti-glycation composition comprises (R)-(-)-2-oxothiazolidine-4-carboxylic acid and an extract of Houttuynia cordata. It was found that the composition exhibits synergism when the concentration of (R)-(-)-2-oxothiazolidine-4-carboxylic acid in a buffer is 1000 ppm, 100 ppm, 1000 ppm, 100 ppm the concentration of the extract in a buffer is 1000 ppm, 1000 ppm, 100 ppm, 100 ppm respectively.

In another embodiment the anti-glycation composition comprises (R)-(-)-2-oxothiazolidine-4-carboxylic acid and an extract of Salacia reticulata. It was found that the composition exhibits synergism when the concentration of (R)-(-)-2-oxothiazolidine-4-carboxylic acid in a buffer is 1000 ppm, 100 ppm, 1000 ppm, the concentration of the extract in a buffer is 1000 ppm, 1000 ppm, 100 ppm respectively.

The plant extracts used in the present invention are butylene glycol extracts obtained from the plant material from leaves, flowers, twigs, seeds, roots, woods, buds, bark and whole plant.

The anti-glycation compositions of the present invention can be used in formulations that include but are not limited to creams, lotions, sprays, emulsions, serums, balm, roll on, gels, ointments, liquids and powders.

The anti-glycation compositions of present invention for cosmetic applications may further comprise cosmetically acceptable excipients selected from list of structurants, emollients, emulsifying agents, diluents/carriers, humectants, preservatives, fragrances, silicones, vitamin and/or derivatives thereof, polyols, chelating agents, vehicles, anti-ageing active agents, free-radical scavengers and antioxidants, neutralizing agents, and the like.

The composition of the present invention may further include structurants. Any suitable structurant can be selected, as will be appreciated by one of ordinary skill in the art. Exemplary structurant suitable for use in the compositions of the present invention include fatty alcohols, thickening agent, fatty acids, fatty acid esters, and fatty acid amides, having fatty chains from 8 to 30 carbons atoms. The structurants, if present, may be provided at concentrations ranging from about 0.1% to about 10.0% by weight of the composition; preferably from about 0.4% to about 5.0 % by weight of the composition.

The composition of the present invention may further include a thickening agent. Any suitable thickening agent can be selected, as will be appreciated by one of ordinary skill in the art. Exemplary thickening agent suitable for use in the compositions of the present invention include alkyloamides, carbomer 934,940,941,960,961, acrylic acid polymers which may be homopolymers, copolymers and cross-polymers, cross linked polyacrylic acid salts, cross linked acrylic copolymers, carboxymethyl cellulose, carboxy vinyl polymers, Hydroxy ethyl cellulose, Hydroxy propyl cellulose, methyl cellulose, Xanthan gum, Carrageenan, Alginic acid salts, Pectin, Gum Arabic, Gatch gum, Karaya gum, Tragacanth gum, Agar powder, Bentonite, cetearyl alcohol, cetyl alcohol, gelatin, gums, magnesium aluminium silicates, ozocarite, paraffin, sodium alginate, Tinovis ADM, Acrylates/C10-30 Alkyl Acrylate Crosspolymer and ammonium Acryloyl - dimethyltaurate / Vinyl pyridine Copolymer/Carbomer, Hydroxyethyl Acrylate / Sodium Acryloyldimethyl Taurate Copolymer (and) Isohexadecane (and) Polysorbate 60. The concentrations of the structurants may be about 0.1% to about 10.0%, preferably about 0.4% by wt to about 5.0% by wt.

The composition of the present invention may further include emollients. Any suitable emollients can be selected, as will be appreciated by one of ordinary skill in the art. Exemplary emollients suitable for use in the compositions of the present invention include lanolin, octyl dodecanol, hexyl decanol, oleyl alcohol, decyl oleate, isopropyl stearate, isopropyl palmitate, isopropyl myristate, hexyl laureate, dioctyl cyclohexane, PPG-15 stearyl ether, isohexadecane, stearic acid, cetyl alcohol, mineral oil, petrolatum, mineral and synthetic waxes, beeswax (Cera alba), paraffin, or waxes and oils of vegetable origin such as candelilla wax (Euphorbia cerifera), carnauba wax (Copernicia cerifera), shea butter (Butyrospermum parkii), cocoa butter (Theobroma cacao), castor oil (Ricinus communis), sunflower oil (Helianthus annuus), olive oil (Olea europaea), coconut oil (Cocos nucifera), palm oil (Elaeis guineensis), wheat germ oil (Triticum vulgare), sweet almond oil (Prunus amygdalus dulces), musk rose seed oil (Rosa moschata), wild soybean oil (Glycine soja), grape seed oil (Vitis vinifera), calendula oil (Calendula officinalis), jojoba oil (Simmonsis chinensis), mango oil (Mangifera indica), avocado oil (Persea gratissima), and/or mixtures thereof, among others. . The emollients, if present, may be provided at concentrations ranging from about 0.1% to about 20.0% by weight of the composition; preferably from about 1 to about 10.0 % by weight of the composition.

The composition of the present invention may further include emulsifying agents. Any suitable emulsifying agents can be selected, as will be appreciated by one of ordinary skill in the art. Exemplary emulsifying agents suitable for use in the compositions of the present invention include oxyalkylenated fatty acid esters of polyols, for example polyethylene glycol stearates, for instance PEG-100 stearate, PEG-50 stearate and PEG-40 stearate, and mixtures thereof, mixture of glyceryl monostearate and of polyethylene glycol stearate (100 EO) (Simulsol 165), oxyalkylenated fatty acid esters of sorbitan comprising, for example, from 20 to 100 EO such as Tween 20 or Tween 60, oxyalkylenated (oxyethylenated and/or oxypropylenated) fatty alcohol ethers; alkoxylated or non-alkoxylated sugar esters, such as sucrose stearate and PEG-20 methylglucose sesquistearate; sorbitan esters such as the sorbitan palmitate (Span 40), esters of diacid and of fatty alcohol, such as dimyristyl tartrate; mixtures of these emulsifiers, for instance the mixture of glyceryl stearate and of PEG-100 stearate (Arlacel 165), and mixtures comprising these emulsifiers, such as the mixture of dimyristyl tartrate, cetearyl alcohol, Pareth-7 and PEG-25 laureth-25, (Cosmacol PSE) , steareth – 2, steareth 21, PPG-15 stearyl ether. The emulsifying agents, if present, may be provided at concentrations ranging from about 0.1% to about 10.0% by weight of the composition; preferably from about 0.4 to about 5.0 % by weight of the composition.

The composition of the present invention may further include diluents/carriers. Any suitable diluents/carriers can be selected, as will be appreciated by one of ordinary skill in the art. Exemplary diluents/carriers suitable for use in the compositions of the present invention include starch, mannitol, lactose, magnesium stearate, talcum, cellulose, glucose, sucrose (or other sugar), magnesium carbonate, gelatin, oil, alcohol, detergents, emulsifiers or water (preferably sterile).
The diluent/carrier, if present, may be provided at concentrations ranging from about 10% to about 90.0% by weight of the composition.
The composition of the present invention may further include humectants. Any suitable humectants can be selected, as will be appreciated by one of ordinary skill in the art. Exemplary humectants suitable for use in the compositions of the present invention include polyols and polyethers such as glycerin, ethylhexylglycerin, caprylyl glycol, pentylene glycol, butylene glycol, propylene glycol and its derivatives, triethylene glycol, polyethylene glycol, Glycereth- 26, Sorbeth-30; panthenol; pyroglutamic acid and its salts and derivatives; amino acids, such as serine, proline, alanine, glutamate or arginine; ectoin and its derivatives; N-(2- hydroxyethyl)acetamide; pyrrolidone carboxylic acid (PCA); /V-lauroyl-pyrrolidone carboxylic acid; /V-lauroyl-L-lysine; /V-alpha-benzoyl-L-arginine; urea; creatine; alpha- and beta- hydroxyacids such as lactic acid, glycolic acid, malic acid, citric acid, tartaric acid or salicylic acid, and their salts; polyglyceryl acrylate; sugars and polysaccharides, such as glucose, isomerate saccharide, sorbitol, pentaerythritol, inositol, xylitol, sorbitol, trehalose and its derivatives, sodium glucuronate, carraghenates (Chondrus crispus) or chitosan; glycosaminoglycans such as hyaluronic acid and its derivatives; aloe vera in any of its forms; honey; soluble collagen; lecithin and phosphatidylcholine; ceramides; cholesterol and its esters; tocopherol and its esters, such as tocopheryl acetate or tocopheryl linoleate; long chain alcohols such as cetearyl alcohol, stearyl alcohol, cetyl alcohol, oleyl alcohol, isocetyl alcohol or octadecan-2-ol; long chain alcohol esters such as lauryl lactate, myristyl lactate or C12-C15 alkyl benzoate; fatty acids such as stearic acid, isostearic acid or palmitic acid; polyunsaturated fatty acids (PUFAs); sorbitans such as sorbitan distearate; glycerides such as glyceryl monoricinoleate, glyceryl monostearate, glyceryl stearate citrate or caprylic acid and capric acid triglyceride; saccharose esters such as saccharose palmitate or saccharose oleate; butylene glycol esters, such as dicaprylate and dicaprate; allantoin, fatty acids such as isopropyl isostearate, isobutyl palmitate, isocetyl stearate, isopropyl laurate, hexyl laurate, decyl oleate, cetyl palmitate, di-n-butyl sebacate, isopropyl myristate, isopropyl palmitate, isopropyl stearate, butyl stearate, butyl myristate, isopropyl linoleate, 2-ehtylhexyl palmitate, 2-ethylhexyl cocoate, decyl oleate, myristyl myristate; squalane, squalene; mink oil; lanolin and its derivatives; acetylated lanolin alcohols; silicon derivatives such as cyclomethicone, dimethicone or dimethylpolysiloxane. The humectants, if present, may be provided at concentrations ranging from about 1% to about 20.0% by weight of the composition; preferably from about 0.1 to about 1.0 % by weight of the composition.

The composition of the present invention may further include cosmetically and dermatologically suitable preservatives. Any suitable cosmetically and dermatologically suitable preservative can be selected, as will be appreciated by one of ordinary skill in the art. Exemplary cosmetically and dermatologically suitable preservatives suitable for use in the compositions of the present invention include 2-phenoxyethanol, para-hydroxybenzoic acid esters, also known as parabens, for instance methyl para-hydroxybenzoate (methyl paraben), ethyl para-hydroxybenzoate (ethyl paraben) and propyl para-hydroxybenzoate (propyl paraben) and mixtures thereof; formaldehyde-releasing agents, for instance imidazolidinylurea or diazolidinylurea; haloalkynyl carbamates, for instance 3-iodo-2-propynyl butyl carbamate (IPBC); caprylyl glycol, also known as 1,2-octanediol; sodium benzoate; N-(3-chloroallyl)-hexaminium chloride (or Quaternium-15); polyhexamethylene biguanide hydrochloride (CTFA name: polyaminopropyl biguanide); alkyltrimethylammonium bromides, for instance dodecyltrimethylammonium bromide, myristyltrimethylammonium bromide and hexadecyltrimethylammonium bromide, ammonium Benzoate, Butyl Benzoate, Calcium Benzoate, Ethyl Benzoate, Isobutyl Benzoate, Isopropyl Benzoate, Magnesium Benzoate, Mea-Benzoate, Methyl Benzoate, Phenyl Benzoate, Potassium Benzoate, Propyl Benzoate, Benzoic Acid, Sodium Benzoate, Propionic Acid, Ammonium Propionate, Calcium Propionate, Magnesium Propionate, Potassium Propionate, Sodium Propionate, Salicylic Acid, Calcium Salicylate, Magnesium Salicylate, Mea-Salicylate, Sodium Salicylate, Potassium Salicylate, Tea-Salicylate, Sorbic Acid, Calcium Sorbate, Sodium Sorbate, Potassium Sorbate, Formaldehyde, Paraformaldehyde, O-Phenylphenol, Mea O-Phenylphenate, Potassium O-Phenylphenate, Sodium O-Phenylphenate, Sodium Sulfite, Ammonium Bisulfite, Ammonium Sulfite, Potassium Sulfite, Potassium Hydrogen Sulfite, Sodium Bisulfite, Sodium Metabisulfite, Potassium Metabisulfite, Chlorobutanol, Butylparaben, Sodium Propoylparaben, Sodium Butylparaben, Potassium Butylparaben, Potassium Propylparaben, 4-Hydroxybenzoic Acid, Methylparaben, Potassium Ethylparaben, Potassium Paraben, Sodium Methylparaben, Sodium Ethylparaben, Sodium Paraben, Potassium Methylparaben, Calcium Paraben, Dehydroacetic Acid, Sodium Dehydroacetate, Formic Acid, Sodium Formate, Dibromohexamidine Isethionate, Phenyl Mercuric Acetate, Phenyl Mercuric Benzoate, Undecylenic Acid, Potassium Undecylenate, Sodium Undecylenate, Calcium Undecylenate, Mea-Undecylenate, Tea-Undecylenate, Triclocarban, Triclosan, Dichlorobenzyl Alcohol, Behentrimonium Chloride, Cetrimonium Bromide, Cetrimonium Chloride, Laurtrimonium Bromide, Laurtrimonium Chloride, Steartrimonium Bromide, Steartrimonium Chloride, Phenoxyisopropanol, Chlorphenesin, Citric Acid (And) Silver Citrate, Iodopropynyl Butylcarbamate, Methylisothiazolinone, Glutaral and mixtures thereof.
The cosmetically and dermatologically suitable preservatives, if present, may be provided at concentrations ranging from about 0.001 to about 5.0 % by weight of the composition; preferably from about 0.1 to about 1.0 % by weight of the composition.

The composition of the present invention may further include a fragrance composition. Any fragrance composition can be selected, as will be appreciated by one of ordinary skill in the art such as a fragrance composition comprising a blend of essential oils and synthetic aroma compounds. Exemplary fragrance composition suitable for use in the compositions of the present invention include benzaldehyde, citral, vanillin, ethyl acetate, fructone, octyl acetate, pentyl butanoate, pentyl pentanoate, methyl salicylate, isoamyl acetate, limonene, citronellol, and mixtures thereof. The blend is often diluted with a carrier like propylene glycol, vegetable oil, or mineral oil. The perfume composition, if present, may be provided at concentrations ranging from about 0.1 to about 5.0 % by weight of the composition.

The composition of the present invention may further include silicone. Any suitable silicone can be selected, as will be appreciated by one of ordinary skill in the art. Exemplary silicone suitable for use in the compositions of the present invention include linear, branched, cross linked, silicone oils, volatile and non volatile silicones such as dimethicone copolyol, dimethylpolysiloxane, diethylpolysiloxane, high molecular weight dimethicone, mixed C1-C30 alkyl polysiloxane, phenyl dimethicone, dimethiconol, cyclopentasiloxane, dimethicone, dimethiconol, mixed C1-C30 alkyl polysiloxane, and mixtures thereof. The silicones, if present, may be provided at concentrations ranging from about 0.01 to about 5.0 % by weight of the composition; preferably from about 0.1 to about 3.0 % by weight of the composition; most preferably from about 0.5 to about 2% by weight of the composition.

The composition of the present invention may further include vitamin. Any suitable vitamin agents can be selected, as will be appreciated by one of ordinary skill in the art. Exemplary vitamin suitable for use in the compositions of the present invention include vitamin A, vitamin B (1-12), vitamin C, vitamin D (2-4), vitamin E, vitamin K, their derivatives, such as acetates, propionates, palmitates, phosphates, alone on in combinations thereof. The vitamins, if present, may be provided at concentrations ranging from about 0.01 to about 5.0 % by weight of the composition; preferably from about 0.05 to about 3.0 % by weight of the composition; most preferably from about 0.5 to about 2% by weight of the composition.

The composition of the present invention may further include polyols. Any suitable polyols can be selected, as will be appreciated by one of ordinary skill in the art. Exemplary polyols suitable for use in the compositions of the present invention include glycerol, ethylene glycol, propylene glycol, pentaerythritol, diglycerol, polyglycerol, their derivatives and combinations thereof. The polyols, if present, may be provided at concentrations ranging from about 0.1 to about 10 % by weight of the composition; preferably from about 0.5 to about 5.0 % by weight of the composition; most preferably from about 1.0 to about 4% by weight of the composition.

The composition of the present invention may further include chelating agents. Any suitable chelating agents can be selected, as will be appreciated by one of ordinary skill in the art. Exemplary chelating agents suitable for use in the compositions of the present invention include dimercaptosuccinic acid (DMSA), Dimercapto-propane sulfonate (DMPS), Alpha lipoic acid (ALA), Calcium disodium versante (CaNa2-EDTA), Disodium EDTA, Dimercaprol (BAL). The chelating agents, if present, may be provided at concentrations ranging from about 0.1 to about 1 % by weight of the composition preferably from about 0.2 to about 0.5 % by weight of the composition.

Various cosmetically acceptable vehicles may be used for the preparation of compositions of the present invention. These may be selected from the group consisting of but not limited to water, alcohols, oils and combinations thereof.

The composition of the present invention may further include anti-ageing active agents. Any suitable anti-ageing active agents can be selected, as will be appreciated by one of ordinary skill in the art. Exemplary anti-ageing active agents suitable for use in the compositions of the present invention include free-radical scavengers, keratolytic agents, vitamins, anti-elastase and anti-collagenase agents, proteins, fatty acid derivatives, steroids, trace elements, bleaching agents, algal and plankton extracts, enzymes and coenzymes, flavonoids, ceramides, tensioning agents and muscle relaxants, and mixtures thereof. The anti-ageing active agents, if present, may be provided at concentrations ranging from about 0.001 to about 10 % by weight of the composition, preferably from about 0.01 to about 5 % by weight of the composition.

The composition of the present invention may further include free-radical scavengers and antioxidants. Any suitable free-radical scavengers and antioxidants can be selected, as will be appreciated by one of ordinary skill in the art. Exemplary free-radical scavengers and antioxidants suitable for use in the compositions of the present invention phosphonic acid derivatives such as ethylenediaminetetra (methylenephosphonic acid), and salts thereof, in particular the sodium salts thereof; guanosine; superoxide dismutase; tocopherol (vitamin E) and its derivatives (acetate); ethoxyquine; lactoferrin; lactoperoxidase, and nitroxide derivatives; superoxide dismutases; glutathione peroxidase; plant extracts with free-radical-scavenging activity, such as the aqueous extract of wheatgerm (Detoxiline), green tea, and mixtures thereof. The free-radical scavengers and antioxidants, if present, may be provided at concentrations ranging from about 0.001 to about 2 % by weight of the composition., preferably from about 0.01 to about 1 % by weight of the composition.

The composition of the present invention may further include one or more neutralizing agents, such as, for example, strong and weak bases. Any suitable neutralizer can be selected, as will be appreciated by one of ordinary skill in the art. Exemplary neutralizers suitable for use in the compositions of the present invention included sodium hydroxide, potassium hydroxide, ammonium hydroxide, diethanolamine, triethanolamine, 2-dimethylamino-2-methyl-1-propanol (DAMP), 2-aminomethyl-1propanol (aminomethyl propanol) (AMP), and the like, or combinations thereof. The neutralizer, if present, may be provided in any amount, e.g., an amount sufficient to achieve a desired pH for the composition. In this respect, the composition preferably has a pH of from about 4-9, more preferably, from about 5-8, and still more preferably from about 5.5-7. Typically, the neutralizer may be present at concentrations ranging from an amount of from about 0.01% -10% by weight of the composition.

In accordance with an aspect of this invention the anti-glycation compositions of the present invention can be prepared by a process, comprising steps of:
a) Mixing the water and humectant to obtain a uniform mix A;
b) Adding viscosity enhancer to uniform mixture obtained in step (a) to form uniform mix B;
c) Adding (R)-(-)-2-oxothiazolidine-4-carboxylic acid and an extract selected from group consisting of Crithmum maritimum extract or Salacia reticulata wood extract or Hydrangea macrophylla leaf extract or Scutellaria baicalensis root extract or Houttuynia cordata whole plant extract to uniform mixture obtained in step (b) to form uniform mix C;
d) Adding neutralizing agent to uniform mixture obtained in step (c) to form uniform mix D;
e) Mixing of emollient, emulsifier, silicone and conditioner separately to form uniform mix E;
f) Mixing uniform mix D obtained in step (d) and uniform mix E obtained in step (e) to form uniform mix F; and
g) Addition of preservatives and fragrances.

Materials and methods
(R)-(-)-2-oxothiazolidine-4-carboxylic acid was obtained from Sigma Aldrich. Houttuynia cordata extract was obtained from Ichimaru Pharcos, Crithmum maritimum extract was obtained from Greentech, Hydrangea macrophylla leaf extract was obtained from Ichimaru Pharcos, Scutellaria baicalensis root extract was obtained from Ichimaru Pharcos and Salacia reticulata wood extract was obtained from Ichimaru Pharcos. The geographical origin of plants Crithmum maritimum is France and that of Hydrangea macrophylla, Houttuynia cordata, Scutellaria baicalensis and Salacia reticulata is Japan.

In accordance with the present invention there is provided a synergistic method for inhibition of glycation using the anti-glycation composition comprises a mixture of (R)-(-)-2-oxothiazolidine-4-carboxylic acid and an extract of a plant material of a plant selected from the group consisting of Crithmum maritimum, Hydrangea macrophylla, Scutellaria baicalensis, Houttuynia cordata and Salacia reticulata. The method comprises the step of obtaining the composition of the present invention and contacting the said composition at the site of glycation.

The examples, which are intended to be purely exemplary of the invention, should therefore not be considered to limit the invention in any way.

Example 1
Anti-glycation activity assay:
Stocks of all plant material extracts (Houttuynia cordata extract; Crithmum maritimum extract; Hydrangea macrophylla leaf extract, Scutellaria baicalensis root extract and Salacia reticulata wood extract) were prepared in phosphate-buffered saline (PBS, pH 10) and the desired concentrations were made by using required stock volume. 100 µl of bovine serum albumin (BSA) (10 mg/ml), 100 µl of fructose (50mg/ml) and 100 µl of prepared extract were taken in an eppendorf (triplicates for each extract) as test sample.

A 100 µl of BSA (10 mg/ml), 100 µl of fructose (50 mg/ml) and 100 µl of Aminoguanidine (10 mM) were taken in an eppendorf as positive control.

A 100 µl of BSA (10mg/ml), 100 µl of fructose (50 mg/ml) and 100 µl of PBS (pH 10) were taken in an eppendorf as solvent/vehicle control.

A 100 µl of BSA (10 mg/ml), 100 µl of fructose (50 mg/ml) and 100 µl of PBS (pH 10)/sample were taken in an eppendorf as balnk.

All samples except blank are heated at 70oC for 3 hrs. After heating, 200 µl of each reaction mixture is transferred to a well of 96-well black microplate and fluorescence is read at excitation wavelength of 380 nm (Ex380nm) and emission wavelength of 440 nm (Em440nm). Fluorescence data is normalized by subtracting values of respective blanks from each test sample, positive control and solvent/vehicle control.

Anti-glycation activity (%) of all the samples is determined by the following formula:

% Anti Glycation activity= (Fcontrol-Fsample/Fcontrol) X100
where,
Fcontrol = Fluorescence of solvent/vehicle control-Fluorescence of solvent/vehicle control blank.
Fsample = Fluorescence of Sample-Fluorescence of sample blank.

Anti-glycation activity of (R)-(-)-2-oxothiazolidine-4-carboxylic acid, Houttuynia cordata extract, Crithmum maritimum extract, Hydrangea macrophylla leaf extract, Scutellaria baicalensis root extract, and Salacia reticulata wood extract at various concentrations is shown in Table 1, Table 2, Table 3, Table 4, Table 5 and Table 6.

Table.1 depicts glycation inhibition activity of (R)-(-)-2-oxothiazolidine-4-carboxylic acid at various concentrations.
Concentration (in ppm) % Inhibition of Glycation
10000 96.7
1000 83.5
100 1.2
10 -2.9
1 -7.0
0.1 -12.6
0.01 -8.6
0.001 -7.6

Form Table 1 it is observed that there is a positive correlation between (R)-(-)-2-oxothiazolidine-4-carboxylic acid concentrations and glycation inhibition.

Table 2 depicts glycation inhibition activity of Crithmum maritimum extract at various concentrations.
Concentration (in ppm) % Inhibition of Glycation
100000 83.3
10000 62.7
1000 -4.7
100 -15.5
10 -14.7
1 -14.6
0.1 -9.7
0.01 -11.5
0.001 -11.7

It is observed from the Table 2 that Crithmum maritimum extract at a concentration of 100000 ppm shows maximal inhibition of about 83.3% with respect to control.

Table 3 depicts glycation inhibition activity of Hydrangea macrophylla leaf extract at various concentrations.

Concentration (in ppm) % Inhibition of Glycation
100000 94.8
10000 76.8
1000 14.2
100 -8.4
10 -11.6
1 -20.0
0.1 -20.9
0.01 -3.9
0.001 -1.1

It is observed from the Table.3 that Hydrangea macrophylla leaf extract at a concentration of 100000 ppm shows maximal inhibition of about 94.8% with respect to control.

Table 4 depicts glycation inhibition activity of Scutellaria baicalensis root extract at various concentrations.
Concentration (in ppm) % Inhibition of Glycation
100000 62.6
10000 70.4
1000 31.9
100 -6.6
10 -3.4
1 -17.7
0.1 -13.1
0.01 -19.6
0.001 -7.3

It can be seen from the Table.4 that Scutellaria baicalensis root extract at a concentration of 100000 ppm shows maximal inhibition of about 62.6% with respect to control.

Table 5 depicts glycation inhibition activity of Salacia reticulata wood extract at various concentrations.

Concentration (in ppm) % Inhibition of Glycation
100000 85.3
10000 70.1
1000 13.7
100 -17.0
10 -4.5
1 -10.5
0.1 -9.5
0.01 -13.1
0.001 10.3

It can be seen from the Table 5 that Salacia reticulata wood extract at a concentration of 100000 ppm shows maximal inhibition of about 85.3% with respect to control.

Table 6 depicts glycation inhibition activity of Houttuynia cordata extract at various concentrations.
Concentration (in ppm) % Inhibition of Glycation
100000 89.9
10000 76.3
1000 59.5
100 -9.7
10 -8.7
1 -16.8
0.1 -13.5
0.01 -25.1
0.001 7.9

It can be seen from the Table 6 that Houttuynia cordata wood extract at a concentration of 100000 ppm shows maximal inhibition of about 89.9% with respect to control.

Example 2
Experiments to demonstrate the synergistic activity of combination of (R)-(-)-2-oxothiazolidine-4-carboxylic acid and Crithmum maritimum extract in accordance with the present invention.

Based on the results obtained in individual glycation inhibition activity in example 1 the combination of (R)-(-)-2-oxothiazolidine-4-carboxylic acid and Crithmum maritimum extract at various concentrations is tested for its effect on inhibiting glycation. The experimental details are present in Table 7.

Table 7 depicts the synergistic anti-glycation activity of combination of R)-(-)-2-oxothiazolidine-4-carboxylic acid and Crithmum maritimum.
(R)-(-)-2-oxothiazolidine-4-carboxylic acid concentration (in ppm) % Glycation inhibition Crithmum maritimum extract concentration (in ppm) % Glycation inhibition Theoretical % Glycation inhibition Synergistic % Glycation inhibition
1000 12.8 1000 -8.2 4.7 20.2

Table 8 depicts the anti-glycation activity of combination of R)-(-)-2-oxothiazolidine-4-carboxylic acid and Crithmum maritimum.
(R)-(-)-2-oxothiazolidine-4-carboxylic acid concentration (in ppm) % Glycation inhibition Crithmum maritimum extract concentration (in ppm) % Glycation inhibition Theoretical % Glycation inhibition Synergistic % Glycation inhibition
100 -18.9 1000 -8.2 -27.1 -14.4
1000 12.8 100 -4.4 8.4 5.3
100 -18.9 100 -4.4 -23.3 -18.0

As observed in Table 7 the combination of (R)-(-)-2-oxothiazolidine-4-carboxylic acid and Crithmum maritimum plant material extract at recited concentrations exhibits synergistic effect in counteracting the glycation.

Example 3

Experiments to demonstrate the synergistic activity of combination of (R)-(-)-2-oxothiazolidine-4-carboxylic acid and Hydrangea macrophylla leaf extract in accordance with the present invention.

Based on the results obtained in individual glycation inhibition activity in example 1 the combination of (R)-(-)-2-oxothiazolidine-4-carboxylic acid and Hydrangea macrophylla leaf extract at various concentration is tested for its effect on inhibiting glycation. The experimental details are given in Table 9.

Table 9: depicts the synergistic anti-glycation activity of combination of (R)-(-)-2-oxothiazolidine-4-carboxylic acid and Hydrangea macrophylla leaf extract.
(R)-(-)-2-oxothiazolidine-4-carboxylic acid concentration (in ppm) % Glycation inhibition Hydrangea macrophylla leaf extract concentration (in ppm) % Glycation inhibition Theoretical % Glycation inhibition Synergistic % Glycation inhibition
10 1.9 1000 -17.8 -15.9 14.4

Table 10 depicts the anti-glycation activity of combination of (R)-(-)-2-oxothiazolidine-4-carboxylic acid and Hydrangea macrophylla leaf extract.

(R)-(-)-2-oxothiazolidine-4-carboxylic acid concentration (in ppm) % Glycation inhibition Hydrangea macrophylla leaf extract concentration (in ppm) % Glycation inhibition Theoretical % Glycation inhibition Synergistic % Glycation inhibition
100 -6.9 1000 -17.8 -24.7 -9.8
100 -6.9 100 -25.9 -32.8 -4.5
100 -6.9 10 -30.0 -36.9 -2.6
10 1.9 100 -25.9 -24.0 1.0
10 1.9 10 -30.0 -28.1 0.5

As observed in Table 9 the combination of (R)-(-)-2-oxothiazolidine-4-carboxylic acid and Hydrangea macrophylla leaf extract at recited concentrations exhibits synergistic effect in counteracting the glycation.

Example 4
Experiments to demonstrate the synergistic activity of combination of (R)-(-)-2-oxothiazolidine-4-carboxylic acid and Scutellaria baicalensis root extract in accordance with the present invention.

Based on the results obtained in individual Glycation Inhibition activity in example 1 the combination of (R)-(-)-2-oxothiazolidine-4-carboxylic acid and Scutellaria baicalensis root extract at various concentration is tested for its effect on inhibiting glycation. The experimental details are given in Table 11.

Table 11 depicts the synergistic anti-glycation activity of combination of (R)-(-)-2-oxothiazolidine-4-carboxylic acid and Scutellaria baicalensis root extract.
(R)-(-)-2-oxothiazolidine-4-carboxylic acid concentration (in ppm) % Glycation inhibition Scutellaria baicalensis root extract concentration (in ppm) % Glycation inhibition Theoretical % Glycation inhibition Synergistic % Glycation inhibition
10 1.9 1000 -24.6 -22.7 3.5

Table 12 depicts the anti-glycation activity of combination of (R)-(-)-2-oxothiazolidine-4-carboxylic acid and Scutellaria baicalensis root extract.
(R)-(-)-2-oxothiazolidine-4-carboxylic acid concentration (in ppm) % Glycation inhibition Scutellaria baicalensis root extract concentration (in ppm) % Glycation inhibition Theoretical % Glycation inhibition Synergistic % Glycation inhibition
10 1.9 100 -22.7 -20.7 -12.8

As observed in Table 11 the combination of (R)-(-)-2-oxothiazolidine-4-carboxylic acid and extract of plant material of Scutellaria baicalensis root extract at recited concentrations exhibits synergistic effect in counteracting the glycation.

Example 5
Experiments to demonstrate the synergistic activity of combination of (R)-(-)-2-oxothiazolidine-4-carboxylic acid and Salacia reticulata wood extract in accordance with the present invention.
Based on the results obtained in individual Glycation Inhibition activity in example 1 the combination of (R)-(-)-2-oxothiazolidine-4-carboxylic acid and Salacia reticulata wood extract at various concentrations is tested for its effect on inhibiting glycation. The experimental details are given in Table 13.

Table 13 depicts the synergistic anti-glycation activity of combination of (R)-(-)-2-oxothiazolidine-4-carboxylic acid and Salacia reticulata wood extract.
(R)-(-)-2-oxothiazolidine-4-carboxylic acid concentration (in ppm) % Glycation inhibition Salacia reticulata wood extract concentration (in ppm) % Glycation inhibition Theoretical % Glycation inhibition Synergistic % Glycation inhibition
1000 -6.7 1000 6.2 -0.5 42.0
100 -27.0 1000 6.2 -20.8 18.3
1000 -6.7 100 -2.3 -9.0 6.3

Table 14 depicts the anti-glycation activity of combination of (R)-(-)-2-oxothiazolidine-4-carboxylic acid and Salacia reticulata wood extract.
(R)-(-)-2-oxothiazolidine-4-carboxylic acid concentration (in ppm) % Glycation inhibition Salacia reticulata wood extract concentration (in ppm) % Glycation inhibition Theoretical % Glycation inhibition Synergistic % Glycation inhibition
100 -27.1 100 -2.3 -29.4 -23.5

As observed in Table 13 the combination of (R)-(-)-2-oxothiazolidine-4-carboxylic acid and Salacia reticulata extract in a buffer solution at recited concentration exhibits synergistic effect in counteracting the glycation.

Example 6

Experiments to demonstrate the synergistic activity of combination of (R)-(-)-2-oxothiazolidine-4-carboxylic acid and Houttuynia cordata extract in accordance with the present invention.

Table 15 depicts the synergistic anti-glycation activity of combination of (R)-(-)-2-oxothiazolidine-4-carboxylic acid and Houttuynia cordata extract.
(R)-(-)-2-oxothiazolidine-4-carboxylic acid concentration (in ppm) % Glycation inhibition Houttuynia cordata extract concentration (in ppm) % Glycation inhibition Theoretical % Glycation inhibition Synergistic % Glycation inhibition
1000 8.9 1000 10.3 19.2 24.2
100 -9.3 1000 10.3 1.0 15.9
1000 16.9 100 1.9 18.7 25.2
100 -0.4 100 1.9 1.4 11.6

Table 16 depicts the anti-glycation activity of combination of (R)-(-)-2-oxothiazolidine-4-carboxylic acid and Houttuynia cordata extract.
(R)-(-)-2-oxothiazolidine-4-carboxylic acid concentration (in ppm) % Glycation inhibition Houttuynia cordata extract concentration (in ppm) % Glycation inhibition Theoretical % Glycation inhibition Synergistic % Glycation inhibition
1000 -9.8 10 -6.3 -16.0 -15.0
100 -31.6 10 -6.3 -37.9 -25.9

As observed in Table 15, the combination of (R)-(-)-2-oxothiazolidine- 4-carboxylic acid and Houttuynia cordata extract in a buffer solution at recited concentration exhibits synergistic effect in counteracting the glycation.

Example 7
An anti-glycation formulation in accordance with the present invention can have the composition as mentioned in Table 17 below.
Table 17: An anti-glycation formulation comprising (R)-(-)-2-oxothiazolidine-4-carboxylic acid and Crithmum maritimum extract.

S. No. Ingredients Amount (volume concentration in %)
A 1 Deionized water To make up 100
2 (R)-(-)-2-oxothiazolidine-4-carboxylic acid 0.001
3
Crithmum maritimum extract 0.1
4 Acrylates/C10-30 alkyl acrylate cross-polymer 0.07
5 Glycerin 5.0
6 Butylene glycol 2.0
7 D-panthenol 0.5
B 8 Triethanolamine 0.06
C 9 Mineral oil 4
10 Cetyl alcohol 3
11 Glycol distearate 3
12 Dimethicone 0.5
13 Allantoin 0.1
D 14 Phenoxyethanol 0.3
15 Fragrance 0.2

Method of preparation
Step 1: Glycerin and deionized water of Phase A was added in a vessel and mixed thoroughly at 27ºC to get a uniform mixture without separation of phases;
Step 2: Acrylates/C10-30 alkyl cross-polymer of Phase A was added to the mixture obtained in step (1) and mixed to get uniform mixture without separation of phases;
Step 3: (R)-(-)-2-oxothiazolidine-4-carboxylic acid and Crithmum maritimum extract of Phase A were added to the mixture obtained in step (2), and mixed to get uniform mixture without separation of phases;
Step 4: Butylene glycol and D-Panthenol of Phase A were added to the mixture obtained in step (3) and mixed to get uniform mixture without separation of phases;
Step 5: The mixture obtained in step (4) was neutralized using ingredient of Phase B;
Step 6: Phase C ingredients were added in a separate vessel and mixed thoroughly to get a uniform mixture without separation of phases;
Step 7: The uniform mixtures obtained in step (5) and step (6) were mixed thoroughly to get a uniform mixture without separation of phases;
Step 8: Phenoxyethanol was added to uniform mixture obtained in step (7) and mixed thoroughly to get a uniform mixture without separation of phases; and
Step 9: Fragrance was added to uniform mixture obtained in step (8) and mixed thoroughly to get a uniform mixture without separation of phases.

Table 18: An anti-glycation formulation comprising (R)-(-)-2-oxothiazolidine-4-carboxylic acid and Hydrangea macrophylla leaf extract.
S. No. Ingredients Amount (volume concentration in %)
A 1 Deionized water To make up 100
2 (R)-(-)-2-oxothiazolidine-4-carboxylic acid 0.001
3
Hydrangea macrophylla leaf extract 0.1
4 Acrylates/C10-30 alkyl acrylate cross-polymer 0.07
5 Glycerin 5.0
6 Butylene glycol 2.0
7 D-panthenol 0.5
B 8 Triethanolamine 0.06
C 9 Mineral oil 4
10 Cetyl alcohol 3
11 Glycol distearate 3
12 Dimethicone 0.5
13 Allantoin 0.1
D 14 Phenoxyethanol 0.3
15 Fragrance 0.2

Method of preparation
Step 1: Glycerin and deionized water of Phase A was added in a vessel and mixed thoroughly at 27ºC to get a uniform mixture without separation of phases;
Step 2: Acrylates/C10-30 alkyl cross-polymer of Phase A was added to the mixture obtained in step (1) and mixed to get uniform mixture without separation of phases;
Step 3: (R)-(-)-2-oxothiazolidine-4-carboxylic acid and Hydrangea macrophylla leaf extract of Phase A were added to the mixture obtained in step (2), and mixed to get uniform mixture without separation of phases;
Step 4: Butylene glycol and D-Panthenol of Phase A were added to the mixture obtained in step (3) and mixed to get uniform mixture without separation of phases;
Step 5: The mixture obtained in step (4) was neutralized using ingredient of Phase B;
Step 6: Phase C ingredients were added in a separate vessel and mixed thoroughly to get a uniform mixture without separation of phases;
Step 7: The uniform mixtures obtained in step (5) and step (6) were mixed thoroughly to get a uniform mixture without separation of phases;
Step 8: Phenoxyethanol was added to uniform mixture obtained in step (7) and mixed thoroughly to get a uniform mixture without separation of phases; and
Step 9: Fragrance was added to uniform mixture obtained in step (8) and mixed thoroughly to get a uniform mixture without separation of phases.

Table 19: An anti-glycation formulation comprising (R)-(-)-2-oxothiazolidine-4-carboxylic acid and Scutellaria baicalensis root extract.

S. No. Ingredients Amount (volume concentration in %)
A 1 Deionized water To make up 100
2 (R)-(-)-2-oxothiazolidine-4-carboxylic acid 0.001
3
Scutellaria baicalensis root extract or 0.1
4 Acrylates/C10-30 alkyl acrylate cross-polymer 0.07
5 Glycerin 5.0
6 Butylene glycol 2.0
7 D-panthenol 0.5
B 8 Triethanolamine 0.06
C 9 Mineral oil 4
10 Cetyl alcohol 3
11 Glycol distearate 3
12 Dimethicone 0.5
13 Allantoin 0.1
D 14 Phenoxyethanol 0.3
15 Fragrance 0.2

Method of preparation
Step 1: Glycerin and deionized water of Phase A was added in a vessel and mixed thoroughly at 27ºC to get a uniform mixture without separation of phases;
Step 2: Acrylates/C10-30 alkyl cross-polymer of Phase A was added to the mixture obtained in step (1) and mixed to get uniform mixture without separation of phases;
Step 3: (R)-(-)-2-oxothiazolidine-4-carboxylic acid and Scutellaria baicalensis root extract of Phase A were added to the mixture obtained in step (2), and mixed to get uniform mixture without separation of phases;
Step 4: Butylene glycol and D-Panthenol of Phase A were added to the mixture obtained in step (3) and mixed to get uniform mixture without separation of phases;
Step 5: The mixture obtained in step (4) was neutralized using ingredient of Phase B;
Step 6: Phase C ingredients were added in a separate vessel and mixed thoroughly to get a uniform mixture without separation of phases;
Step 7: The uniform mixtures obtained in step (5) and step (6) were mixed thoroughly to get a uniform mixture without separation of phases;
Step 8: Phenoxyethanol was added to uniform mixture obtained in step (7) and mixed thoroughly to get a uniform mixture without separation of phases; and
Step 9: Fragrance was added to uniform mixture obtained in step (8) and mixed thoroughly to get a uniform mixture without separation of phases.

Table 20: An anti-glycation formulation comprising (R)-(-)-2-oxothiazolidine-4-carboxylic acid and Houttuynia cordata extract.

S. No. Ingredients Amount (volume concentration in %)
A 1 Deionized water To make up 100
2 (R)-(-)-2-oxothiazolidine-4-carboxylic acid 0.001
3
Houttuynia cordata extract or 0.01
4 Acrylates/C10-30 alkyl acrylate cross-polymer 0.07
5 Glycerin 5.0
6 Butylene glycol 2.0
7 D-panthenol 0.5
B 8 Triethanolamine 0.06
C 9 Mineral oil 4
10 Cetyl alcohol 3
11 Glycol distearate 3
12 Dimethicone 0.5
13 Allantoin 0.1
D 14 Phenoxyethanol 0.3
15 Fragrance 0.2

Method of preparation
Step 1: Glycerin and deionized water of Phase A was added in a vessel and mixed thoroughly at 27ºC to get a uniform mixture without separation of phases;
Step 2: Acrylates/C10-30 alkyl cross-polymer of Phase A was added to the mixture obtained in step (1) and mixed to get uniform mixture without separation of phases;
Step 3: (R)-(-)-2-oxothiazolidine-4-carboxylic acid and Houttuynia cordata plant extract of Phase A were added to the mixture obtained in step (2), and mixed to get uniform mixture without separation of phases;
Step 4: Butylene glycol and D-Panthenol of Phase A were added to the mixture obtained in step (3) and mixed to get uniform mixture without separation of phases;
Step 5: The mixture obtained in step (4) was neutralized using ingredient of Phase B;
Step 6: Phase C ingredients were added in a separate vessel and mixed thoroughly to get a uniform mixture without separation of phases;
Step 7: The uniform mixtures obtained in step (5) and step (6) were mixed thoroughly to get a uniform mixture without separation of phases;
Step 8: Phenoxyethanol was added to uniform mixture obtained in step (7) and mixed thoroughly to get a uniform mixture without separation of phases; and
Step 9: Fragrance was added to uniform mixture obtained in step (8) and mixed thoroughly to get a uniform mixture without separation of phases.

Table 21: An anti-glycation formulation comprising (R)-(-)-2-oxothiazolidine-4-carboxylic acid and Salacia reticulata wood extract.

S. No. Ingredients Amount (volume concentration in %)
A 1 Deionized water To make up 100
2 (R)-(-)-2-oxothiazolidine-4-carboxylic acid 0.001
3
Salacia reticulata wood extract 0.01
4 Acrylates/C10-30 alkyl acrylate cross-polymer 0.07
5 Glycerin 5.0
6 Butylene glycol 2.0
7 D-panthenol 0.5
B 8 Triethanolamine 0.06
C 9 Mineral oil 4
10 Cetyl alcohol 3
11 Glycol distearate 3
12 Dimethicone 0.5
13 Allantoin 0.1
D 14 Phenoxyethanol 0.3
15 Fragrance 0.2

Method of preparation
Step 1: Glycerin and deionized water of Phase A was added in a vessel and mixed thoroughly at 27ºC to get a uniform mixture without separation of phases;
Step 2: Acrylates/C10-30 alkyl cross-polymer of Phase A was added to the mixture obtained in step (1) and mixed to get uniform mixture without separation of phases;
Step 3: (R)-(-)-2-oxothiazolidine-4-carboxylic acid and Salacia reticulata wood extract of Phase A were added to the mixture obtained in step (2), and mixed to get uniform mixture without separation of phases;
Step 4: Butylene glycol and D-Panthenol of Phase A were added to the mixture obtained in step (3) and mixed to get uniform mixture without separation of phases;
Step 5: The mixture obtained in step (4) was neutralized using ingredient of Phase B;
Step 6: Phase C ingredients were added in a separate vessel and mixed thoroughly to get a uniform mixture without separation of phases;
Step 7: The uniform mixtures obtained in step (5) and step (6) were mixed thoroughly to get a uniform mixture without separation of phases;
Step 8: Phenoxyethanol was added to uniform mixture obtained in step (7) and mixed thoroughly to get a uniform mixture without separation of phases; and
Step 9: Fragrance was added to uniform mixture obtained in step (8) and mixed thoroughly to get a uniform mixture without separation of phases.

Claims:

1. An anti-glycation composition comprising:
a) (R)-(-)-2-oxothiazolidine-4-carboxylic acid; and
b) plant extract of Crithmum maritimum.
2. The anti-glycation composition as claimed in claim 1, wherein said composition comprises 1000 ppm of (R)-(-)-2-oxothiazolidine-4-carboxylic acid and 1000 ppm of Crithmum maritimum extract present in a buffer solution.
3. The anti-glycation composition as claimed in claim 2, wherein said buffer is phosphate buffer saline.
4. The anti-glycation composition as claimed in claim 1, wherein said plant extract is a butylene glycolic extract of whole plant Crithmum maritimum.
5. An anti-glycation composition comprising:
a) (R)-(-)-2-oxothiazolidine-4-carboxylic acid; and
b) plant extract of Hydrangea macrophylla.
6. The anti-glycation composition as claimed in claim 5, wherein said composition comprises 10 ppm of (R)-(-)-2-oxothiazolidine-4-carboxylic acid and 1000 ppm of Hydrangea macrophylla extract present in a buffer solution.
7. The anti-glycation composition as claimed in claim 6, wherein said buffer is phosphate buffer saline.
8. The anti-glycation composition as claimed in claim 5, wherein said Hydrangea macrophylla plant extract is a butylene glycolic extract of leaves of Hydrangea macrophylla.
9. An anti-glycation composition comprising:
a) (R)-(-)-2-oxothiazolidine-4-carboxylic acid; and
b) plant extract of Scutellaria baicalensis.
10. The anti-glycation composition as claimed in claim 9, wherein said composition comprises 10 ppm of (R)-(-)-2-oxothiazolidine-4-carboxylic acid and 1000 ppm of Scutellaria baicalensis extract present in a buffer solution.
11. The anti-glycation composition as claimed in claim 10, wherein said buffer is phosphate buffer saline.
12. The anti-glycation composition as claimed in claim 9, wherein said Scutellaria baicalensis plant extract is a butylene glycolic extract of wood of Scutellaria baicalensis.
13. An anti-glycation composition comprising:
a) (R)-(-)-2-oxothiazolidine-4-carboxylic acid; and
b) plant extract of Houttuynia cordata.;
14. The anti-glycation composition as claimed in claim 13, wherein said composition comprises 1000 ppm of (R)-(-)-2-oxothiazolidine-4-carboxylic acid and 1000 ppm of Houttuynia cordata extract present in a buffer solution.
15. The anti-glycation composition as claimed in claim 13, wherein said composition comprises 100 ppm of (R)-(-)-2-oxothiazolidine-4-carboxylic acid and 1000 ppm of Houttuynia cordata extract present in a buffer solution.
16. The anti-glycation composition as claimed in claim 13, wherein said composition comprises 1000 ppm of (R)-(-)-2-oxothiazolidine-4-carboxylic acid and 100 ppm of Houttuynia cordata extract present in a buffer solution.
17. The anti-glycation composition as claimed in claim 13, wherein said composition comprises 100 ppm of (R)-(-)-2-oxothiazolidine-4-carboxylic acid and 100 ppm of Houttuynia cordata extract present in a buffer solution.
18. The anti-glycation composition as claimed in claims 14 to 17, wherein said buffer is phosphate buffer saline.
19. The anti-glycation composition as claimed in claim 13, wherein said Houttuynia cordata plant extract is obtained from flowers, leaves, twigs, bark, buds, wood, roots, seeds and whole plant.
20. The anti-glycation composition as claimed in claim 19, wherein said Houttuynia cordata plant extract is butylene glycolic extract of whole plant of Houttuynia cordata.
21. An anti-glycation composition comprising:
a) (R)-(-)-2-oxothiazolidine-4-carboxylic acid; and
b) plant extract of Salacia reticulata.
22. The anti-glycation composition as claimed in claim 21, wherein said composition comprises 1000 ppm of (R)-(-)-2-oxothiazolidine-4-carboxylic acid and 1000 ppm of Salacia reticulata extract present in a buffer solution.
23. The anti-glycation composition as claimed in claim 21, wherein said composition comprises 100 ppm of (R)-(-)-2-oxothiazolidine-4-carboxylic acid and 1000 ppm of Salacia reticulata extract present in a buffer solution.
24. The anti-glycation composition as claimed in claim 21, wherein said composition comprises 1000 ppm of (R)-(-)-2-oxothiazolidine-4-carboxylic acid and 100 ppm of Salacia reticulata extract present in a buffer solution.
25. The anti-glycation composition as claimed in claims 22, 23 and 24 wherein said buffer is phosphate buffer saline.
26. The anti-glycation composition as claimed in claim 21, wherein said Salacia reticulata plant extract is a butylene glycolic extract of root of Salacia reticulata.
27. The anti-glycation composition as claimed in claim 1, wherein said composition further comprises cosmetically acceptable excipients selected from structurants, emollients, emulsifiers, diluents, humectants, actives, preservatives and fragrances.
28. The anti-glycation composition as claimed in claim 1, wherein said composition is prepared in the form of personal care creams, lotions, sprays, emulsions, serums, balm, roll on, gels, ointments, liquids, topical powders.
29. The anti-glycation composition as claimed in claim 5, wherein said composition further comprises cosmetically acceptable excipients selected from structurants, emollients, emulsifiers, diluents, humectants, actives, preservatives and fragrances.
30. The anti-glycation composition as claimed in claim 5, wherein said composition is prepared in the form of personal care creams, lotions, sprays, emulsions, serums, balm, roll on, gels, ointments, liquids, topical powders.
31. The anti-glycation composition as claimed in claim 9, wherein said composition further comprises cosmetically acceptable excipients selected from structurants, emollients, emulsifiers, diluents, humectants, actives, preservatives and fragrances.
32. The anti-glycation composition as claimed in claim 9, wherein said composition is prepared in the form of personal care creams, lotions, sprays, emulsions, serums, balm, roll on, gels, ointments, liquids, topical powders.
33. The anti-glycation composition as claimed in claim 13, wherein said composition further comprises cosmetically acceptable excipients selected from structurants, emollients, emulsifiers, diluents, humectants, actives, preservatives and fragrances.
34. The anti-glycation composition as claimed in claim 13, wherein said composition is prepared in the form of personal care creams, lotions, sprays, emulsions, serums, balm, roll on, gels, ointments, liquids, topical powders.
35. The anti-glycation composition as claimed in claim 21, wherein said composition further comprises cosmetically acceptable excipients selected from structurants, emollients, emulsifiers, diluents, humectants, actives, preservatives and fragrances.
36. The anti-glycation composition as claimed in claim 21, wherein said composition is prepared in the form of personal care creams, lotions, sprays, emulsions, serums, balm, roll on, gels, ointments, liquids, topical powders.
37. A method of preparing an anti-glycation composition as claimed in claim 1 said method comprising the steps of:
a. mixing water and at least one humectant in a first container to obtain a uniform mix A;
b. mixing at least one viscosity enhancer to mix A to obtain a uniform mix B;
c. mixing (R)-(-)-2-oxothiazolidine-4-carboxylic acid and an extract of plant material of Crithmum maritimum, to mix B to obtain a uniform mix C;
d. mixing at least one neutralizer to mix C to obtain a uniform mix D;
e. mixing at least one emollient, at least one emulsifier, at least one silicone, and at least one conditioner in a second container to obtain a uniform mix E;
f. mixing mix D, and mix E together to obtain a uniform mix F;
g. mixing at least one preservative to mix F to obtain a uniform mix G; and
h. mixing at least one fragrance to mix G to obtain said formulation.
38. A method of preparing an anti-glycation composition as claimed in claim 5, said method comprising the steps of:
a. mixing water and at least one humectant in a first container to obtain a uniform mix A;
b. mixing at least one viscosity enhancer to mix A to obtain a uniform mix B;
c. mixing (R)-(-)-2-oxothiazolidine-4-carboxylic acid and an extract of plant material of Hydrangea macrophylla to mix B to obtain a uniform mix C;
d. mixing at least one neutralizer to mix C to obtain a uniform mix D;
e. mixing at least one emollient, at least one emulsifier, at least one silicone, and at least one conditioner in a second container to obtain a uniform mix E;
f. mixing mix D, and mix E together to obtain a uniform mix F;
g. mixing at least one preservative to mix F to obtain a uniform mix G; and
h. mixing at least one fragrance to mix G to obtain said formulation.
39. A method of preparing an anti-glycation composition as claimed in claim 9, said method comprising the steps of:
a. mixing water and at least one humectant in a first container to obtain a uniform mix A;
b. mixing at least one viscosity enhancer to mix A to obtain a uniform mix B;
c. mixing (R)-(-)-2-oxothiazolidine-4-carboxylic acid and an extract of plant material of Scutellaria baicalensis, to mix B to obtain a uniform mix C;
d. mixing at least one neutralizer to mix C to obtain a uniform mix D;
e. mixing at least one emollient, at least one emulsifier, at least one silicone, and at least one conditioner in a second container to obtain a uniform mix E;
f. mixing mix D, and mix E together to obtain a uniform mix F;
g. mixing at least one preservative to mix F to obtain a uniform mix G; and
h. mixing at least one fragrance to mix G to obtain said formulation.
40. A method of preparing an anti-glycation composition as claimed in claim 13 , said method comprising the steps of:
a. mixing water and at least one humectant in a first container to obtain a uniform mix A;
b. mixing at least one viscosity enhancer to mix A to obtain a uniform mix B;
c. mixing (R)-(-)-2-oxothiazolidine-4-carboxylic acid and an extract of plant material of Houttuynia cordata to mix B to obtain a uniform mix C;
d. mixing at least one neutralizer to mix C to obtain a uniform mix D;
e. mixing at least one emollient, at least one emulsifier, at least one silicone, and at least one conditioner in a second container to obtain a uniform mix E;
f. mixing mix D, and mix E together to obtain a uniform mix F;
g. mixing at least one preservative to mix F to obtain a uniform mix G; and
h. mixing at least one fragrance to mix G to obtain said formulation.
41. A method of preparing an anti-glycation composition as claimed in claim 21, said method comprising the steps of:
a. mixing water and at least one humectant in a first container to obtain a uniform mix A;
b. mixing at least one viscosity enhancer to mix A to obtain a uniform mix B;
c. mixing (R)-(-)-2-oxothiazolidine-4-carboxylic acid and an extract of plant material of Salacia reticulata to mix B to obtain a uniform mix C;
d. mixing at least one neutralizer to mix C to obtain a uniform mix D;
e. mixing at least one emollient, at least one emulsifier, at least one silicone, and at least one conditioner in a second container to obtain a uniform mix E;
f. mixing mix D, and mix E together to obtain a uniform mix F;
g. mixing at least one preservative to mix F to obtain a uniform mix G; and
h. mixing at least one fragrance to mix G to obtain said formulation.
42. A method of inhibiting glycation, wherein the method comprises applying the compositions of claim 1.
43. A method of inhibiting glycation, wherein the method comprises applying the compositions of claim 5.
44. A method of inhibiting glycation, wherein the method comprises applying the compositions of claim 9.
45. A method of inhibiting glycation, wherein the method comprises applying the compositions of claim 13.

46. A method of inhibiting glycation, wherein the method comprises applying the compositions of claim 21.